A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Launched by ALLERGAN · May 20, 2016
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Participant has androgenetic alopecia (AGA)
- • Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.
- Exclusion Criteria:
- • History of hair loss for reasons other than AGA
- • Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft
- • Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth
- • Hair-weaving within 6 months
- • Use of hair colorants or dyes within 6 months.
About Allergan
Allergan, a global leader in pharmaceutical innovation, specializes in developing and commercializing a diverse portfolio of advanced therapeutic and aesthetic products. With a commitment to improving the health and well-being of patients, Allergan conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies across various medical fields, including ophthalmology, dermatology, and neuroscience. The company is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring that its research not only advances medical science but also meets the needs of healthcare providers and patients worldwide. Through strategic collaborations and a focus on scientific excellence, Allergan continues to drive advancements in treatment options and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wichita, Kansas, United States
Fridley, Minnesota, United States
Hot Springs, Arkansas, United States
San Diego, California, United States
Portland, Oregon, United States
Austin, Texas, United States
Clinton Township, Michigan, United States
Santa Rosa, California, United States
Chicago, Illinois, United States
Portland, Oregon, United States
Greer, South Carolina, United States
Lynchburg, Virginia, United States
Little Rock, Arkansas, United States
Minneapolis, Minnesota, United States
Winston Salem, North Carolina, United States
Cleveland, Ohio, United States
Hershey, Pennsylvania, United States
Katy, Texas, United States
Patients applied
Trial Officials
Joan-En Lin
Study Director
Allergan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials